key: cord-0741624-mcek2295
authors: Sun, Lijun; Shen, Lijun; Fan, Junfen; Gu, Fengjun; Hu, Mei; An, Yiran; Zhou, Qing; Fan, Huahao; Bi, Jingfeng
title: Clinical Features of Patients with Coronavirus Disease 2019 (COVID‐19) from a Designated Hospital in Beijing, China
date: 2020-05-05
journal: J Med Virol
DOI: 10.1002/jmv.25966
sha: 13c23e37aa9c588e22ca4c388fcaae05c8d9503a
doc_id: 741624
cord_uid: mcek2295

Clinical and laboratory data available on patients with coronavirus disease 2019 (COVID‐19) in Beijing, China remain extremely limited. Here, we summarized the clinical characteristics of patients with COVID‐19 in a designated hospital in Beijing, China. 55 patients with laboratory‐confirmed SARS‐CoV‐2 infection were admitted to Beijing 302 Hospital and enrolled in this study. Demographic data, symptoms, comorbidities, laboratory values, treatments, and clinical outcomes were all collected and retrospectively analyzed. 15 (27.3%) of the patients had non‐severe symptom, the mean age was 44.0 years (interquartile range 34.0‐56.0), and median incubation period was 7.5 days (interquartile range 5.0‐11.8). 26 (47.3%) patients had exposure history in Wuhan while 20 (36.4%) were associated with familial clusters. 18 (32.7%) had underlying comorbidities including hypertension. The most common symptoms of illness were fever (45, 81.8%), 51 (92.7%) patients had abnormal findings on chest CT. Laboratory findings showed that neutrophil count, percentage of lymphocyte, percentage of eosinophil, eosinophil count, erythrocyte sedimentation rate, albumin, and serum ferritin are potential risk factors for patients with poor prognosis. 26 patients (47.3%) were still hospitalized while 29 (52.7%) had been discharged at this point. Compared with patients in Wuhan, the symptoms of patients in Beijing are relatively mild. Older age, more comorbidities, and more abnormal prominent laboratory markers were associated with severe condition. On the basis of antiviral drugs, antibiotics treatment, appropriate dosage of corticosteroid and gamma globulin therapy significantly improve patients’ outcomes. Early identification and timely medical treatment are important to reduce the severity of patients with COVID‐19. This article is protected by copyright. All rights reserved.

cardiovascular disease (6.7%).

Of the 53 patients who had the body temperature records, 45 (81.8%) patients' highest body temperature before hospital admission were higher than 37.3 °C, suggesting fever is still one of the typical symptoms of COVID-19.

Except for fever, the common symptoms of the enrolled patients on admission were cough (26, 47.3%), fatigue (14, 25.5%), expectoration (13, 23.6%), muscle ache (10, 18.2%), sore throat (8, 14.5%), anorexia (7, 12.7%), dizziness (6, 10.9%), headache (6, 10.9%), shortness of breath (5, 9.1%), chills (4, 7.3%), dry cough (3, 5.5%), and dyspnea (3, 5.5%). According to imaging examination, the majority (51, 92.7%) had abnormal lung findings, with 44 (80%) patients showed bilateral pneumonia and 8 (14.5%) had unilateral lesions. 30 (54.5%) patients had atypical inflammatory changes, 16 (29.1%) showed no clear inflammatory changes, and 9 (16.4%) showed typical ground-glass opacity ( Figure 1 ). 32 (58.2%) patients showed substantial lung inflammation, 16 (29.1%) showed no inflammation as well as 7 (12.7%) showed a little inflammation on lungs.

This article is protected by copyright. All rights reserved.

Further analysis found that compared with non-severe patients, severe patients were more likely to occur shortness of breath (26.7% vs. 2.5%) and lung inflammation, especially massive lung inflammation (86.7% vs. 47.5%) (p<0.05) at admission. And hypertension (40.0% vs. 5.0%), untimely treatment (duration from illness onset to first admission and duration from other hospitals to designated hospitals) could exacerbate the COVID-19 disease severity (p<0.05).

In addition, age (37.0 vs. 54.5), hypertension (3.4% vs. 26.9%), anorexia (3.4% vs. 23.1%), shortness of breath (0.0% vs. 19.2 %), lung inflammation at admission (especially massive inflammation (37.9% vs. 80.8%)), type of lesion at admission (especially typical ground glass opacity (6.9% vs. 26.9%)), duration from illness onset to first admission (days) (1.0 vs. 4.0), duration from other hospitals to designated hospitals (days) (3.0 vs. 6.0) could significantly influence the clinical outcomes (discharge or non-discharge) of patients (p<0.05).

To determine the major clinical features that appeared during COVID-19 progression, the dynamic changes in tested clinical laboratory parameters, including blood routine, blood chemistry, liver function, kidney function, urine routine, and blood gas were tracked from 20 January 2020 to 15 February 2020.

We collected the results of laboratory examinations of all patients since admission. During hospitalization, the same laboratory index may be required for Accepted Article multiple inspections at different time points based on patients' conditions. As long as the specific laboratory index occurred abnormal (increased or decreased) once, we consider this index for that patient is abnormal. During the hospitalization of the 55 patients from 20 January 2020 to 15 February 2020, a total of 152 laboratory parameters were abnormal for all patients, 123 abnormalities occurred on non-severe patients, 139 abnormalities on patients with severe symptoms, 146 on hospitalized patients, and 127 on patients discharged ( Table 2 ).

The number of top 60% abnormal parameters among all patients were 18 ( Figure 1A) , and that of non-severe patients were 7 ( Figure 1B ), severe patients were 45 ( Figure 1C ), hospitalized patients were 34 (Figure 2A) , and discharged patients were 3 ( Figure 2B ). The top 5 abnormal laboratory parameters for all patients were percentage of neutrophil (80.0%, represent for frequency), interleukin-6 (74.5%), iron (74.5%), percentage of lymphocyte (72.7%), lactic acid (72.7%), percentage of eosinophil (72.7%), and erythrocyte sedimentation rate (ESR) (72.7%). The top 5 abnormal test indicators for non-severe patients were interleukin-6 (72.5%), iron (72.5%), percentage of neutrophil (72.5%), lactic acid (67.5%), and percentage of lymphocyte (62.5%). The most abnormal parameters for severe patients were albumin (100.0%), percentage of lymphocyte (100.0%), pro-brain natriuretic peptide (proBNP) (100.0%), percentage of eosinophil (100.0%), eosinophil count (100.0%), ESR (100.0%), serum ferritin This article is protected by copyright. All rights reserved.

(100.0%), percentage of neutrophil (100.0%), and neutrophil count (100.0%). The most abnormal parameters of hospitalized patients were percentage of neutrophil (96.2%), percentage of lymphocyte (92.3%), lactic acid (92.3%), percentage of eosinophil (92.3%), ESR (92.3%), serum ferritin (92.3%), and neutrophil count (92.3%). The top five abnormal indicators of discharged patients were interleukin-6 (69.0%), iron (69.0%), percentage of neutrophil (65.5%), percentage of lymphocyte (55.2%), and lactic acid levels (55.2%). Further analysis found that the abnormality ratio of 47 parameters of severe patients was higher than that of non-severe patients (p<0.05), and the abnormality ratio of 33 indicators of hospitalized patients was higher than that of discharged patients (p<0.05). The potential risk factors of neutrophil count, percentage of lymphocyte, percentage of eosinophil, eosinophil count, ESR, albumin, and serum ferritin could help clinicians to identify patients with poor prognosis at an early stage (Table 2 and   supplementary table 1) .

The clinical treatment and outcomes of the 55 patients were shown in Table 3 .

As of February 15, 2020, 26 patients (47.3%) were still hospitalized whereas a total of 29 patients (52.7%) had been discharged. Significantly more severe cases received mechanical ventilation (non-invasive: 33.3% vs. 0%, p=0.001; invasive: 20.0% vs.0%, p=0.017) as compared with non-severe cases. Only 1 patient This article is protected by copyright. All rights reserved.

(12.5%) of those who received mechanical ventilation had been discharged while the other 7 patients (87.5%) were still hospitalized at this point. 48 (87.3%) patients received antiviral therapy, 51 (92.7%) patients were given interferon alpha inhalation. 43 (78.2%) cases received lopinavir/ritonavir treatment and 36 (65.5%) patients were given lopinavir/ritonavir plus interferon alpha inhalation treatment. 29 (52.7%) were given empirical antibiotic treatment, 25 (45.5%) were adopted systematic corticosteroid and 22 (40.0%) received gamma globulin treatment. Moreover, blood purification therapy was adopted in 3 (20.0%) severe cases but none in non-severe cases (p=0.004). Chinese medicine was given to 6 (10.9%) cases and 1 (1.8%) patient received convalescent plasma therapy. On the basis of antiviral drugs, antibiotics treatment, appropriate dosage of corticosteroid and gamma globulin therapy significantly improve patients' outcomes (p<0.05).

As of March 24, 2020, SARS-CoV-2 infection cases were reported in more than 334 thousand cases, which caused more than 14000 deaths and spread to 189 countries and areas. The number of infected patients is still increasing rapidly. The clinical characteristics of early cases of COVID-19 in Wuhan City have been reported a lot [Chen et al., 2020; Huang et al., 2020; Li et al., 2020; Shi et al., 2020; Wang et al., 2020] . As the capital of China, Beijing, the infection and clinical characteristics of patients have attracted much attention, but few of them Accepted Article has been reported. Among the 55 patients we analyzed, there were many cases (20, 36.4%) of family clustering in our study. There is no doubt that SARS-CoV-2 has a strong human to human transmission characteristics as previously reported [Nishiura et al., 2020; Yu et al., 2020] .

More than half of the patients in Beijing 302 hospital are male (31, 56.4%), and with a wide range of age, including a 3-year-old boy and an 85-year-old lady.

Compared with the initially reported high proportion of severe patients and high fatality in Wuhan, the symptoms of patients in Beijing are relatively mild and there is only one dead patient caused by claustrophobia, and this case is excluded from this study [Xu et al., 2020] .

Here, we studied the effect of seven complications on the severity and outcomes of patients in detail. Among them, whether suffering from hypertension is the only risk factor for severe patients and non-severe patients as well as for hospitalized patients and discharged patients. Of the 55 patients with positive SARS-CoV-2 nucleic acid test, 45 (81.8%) had a body temperature of over 37.3 °C, 51 (92.7%) had abnormal chest CT findings, suggesting abnormal body temperature and lung CT are still important indicators for COVID-19 diagnosis.

Among the abnormal laboratory test we screened, indexes included blood routine, T cell subsets, infection-related biomarkers, liver function, glucose,

There are several limitations in our study. First, only 55 patients with confirmed SARS-CoV-2 were included. A number of patients were continually being admitted to hospital as data were being collected, and thus we obtained data on most but not all of the patients with laboratory confirmed infection in Beijing 302 Hospital during the study period. It would be better to include as many patients as possible in Beijing and a larger cohort study would help to further define the demographic data, symptoms, comorbidities, laboratory values, treatments, and clinical outcomes. Second, kinetics of viral load and antibody titers were not demonstrated in this study. Third, we no doubt missed patients who were asymptomatic. Fourth, a number of patients had not been discharged at the time of study submission, so we are unable to estimate either the case mortality rate or the predictors of fatality. More effort should be made to answer these questions in future studies. However, the data in this study permit an early assessment of the epidemiological and clinical characteristics of COVID-19 in Beijing, China.

Although information on COVID-19 has increased rapidly since the emergence of SARS-CoV-2, many problems still remain unresolved. The clinical manifestation of COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. During our study period, there was no data reported on asymptomatic infections in Beijing 302 hospital. Our understanding of

For the patients after-discharge, according to the diagnostic and treatment guideline for COVID-19 issued by Chinese National Health Committee (version 6-7), the designated hospitals should contact the primary healthcare facilities where the patients reside and patients' medical record should be shared afterdischarge, and it is recommended for patients to live in a single well-ventilated room if possible. And returning to the hospitals for follow-up and re-visit in two and four weeks after discharge is also recommended.

To sum up, the COVID-19 infection was of clustering onset. It can infect people of all ages. Older age, more comorbidities, and more abnormal prominent laboratory markers were associated with more severe condition. An effective diagnosis and timely treatment program can effectively reduce the severity of patients' conditions and significantly reduce patients' mortality. More efforts should be made to better understand the whole spectrum and pathophysiology of COVID-19. This article is protected by copyright. All rights reserved. Tables   Table 1. >39.0 5(9.1) 4(10.0) 1(6.7) 3(11.5) 2(6.9) missing 2(3.6) 1(2.5) 1(6.7) 2(7.7) 0(0.0) 

Presumed Asymptomatic Carrier Transmission of COVID-19

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic